** U.S.-listed shares of Aurora Cannabis drop 3.1 pct to $6.95 premarket after results
** Net revenue surged more than 4x in Q2; still, co swung to a loss as costs surged
** Two brokerages - BMO and Eight Capital - say results were in line with their expectations
** BMO continues to see significant uncertainty in schedules for increasing cannabis production in coming quarters due to challenges associated with growing at scale, Health Canada licensing delays, and supply chain bottlenecks
** ACB is down 44 pct from its all-time high of $12.53 in mid-October
** Tilray rises 1.1 pct ahead of its Q3 report due after the closing bell on Tuesday
** Other cannabis stocks fall: Canopy Growth dips 0.6 pct, set to post third quarter numbers on Thursday; Cronos Group Inc down 1 pct, Aphria Inc falls 2.5 pct (Reporting by Medha Singh in Bengaluru)
Our Standards: The Thomson Reuters Trust Principles.